Calixa Therapeutics calixainc.com


Public lists: Pharma Startups (6570)

Calixa Therapeutics is focused on developing, acquiring and commercializing hospital-based anti-infective therapies

Calixa Therapeutics is focused on developing, acquiring and commercializing hospital-based anti-infective therapies

Company (Acquired)

Phone: 858-480-2420

Fax: (877) 393-3519

12481 High Bluff Drive
Suite 150
San Diego, 92130
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Calixa Therapeutics $0M Dec 14, 2009
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Calixa Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors

Competitors

Company Status Description Investors

Allon Therapeutics

Vancouver, British Columbia, Canada
AcquiredAllon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human efficacy trials underway pursuing three large underserved markets: Alzheimer's disease, schizophrenia and cognitive impairment.The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuroprotection CompanyTM) and based in Vancouver.Login to see details

Hyperion Therapeutics

South San Francisco, California, United States
AcquiredHyperion Therapeutics is a privately held specialty therapeutics company focused on the development of therapies that address needs in the areas of gastroenterology and hepatology. In partnership with Ucyclyd Pharma, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Methods for treating intrapulmonary infections Oct 13, 2014 Aug 08, 2017 Patent
Ceftolozane antibiotic compositions Apr 11, 2014 Jun 02, 2015 Patent
Ceftolozane-tazobactam pharmaceutical compositions May 22, 2014 Mar 03, 2015 Patent
Solid forms of ceftolozane May 28, 2014 Dec 09, 2014 Patent
Methods for treating intrapulmonary infections Nov 21, 2014 Application
See all 13 patents